CRP and respiratory distress syndrome in premature infants: PUFAs have demonstrated the ability to prevent the development of inflammation by reducing blood levels of inflammatory biomarkers such as interleukin-6 (IL-6), TNF-α, CRP, serum amyloid A, and white blood cell counts.69 Several RCTs have explored the efficacy of PUFAs, especially omega-3, in IRDs, and five meta-analyses were found in literature.